And several clinical studies have investigated that ER+PR+, ER+PR- and ER-PR+ subtypes showed distinct clinicopathological characteristics and outcomes although they all belong to luminal breast cancer [18–20]. This evidence concerns the gene ESR1 and breast carcinoma.